Search research articles
Contact Us
Filters
Showing results (81-90 of 99) with videos related to
Page
of 10
Sort By:
Journal of Crohn'S & Colitis
|
April 17, 2019
Long-term Clinical Effectiveness of Ustekinumab in Patients with Crohn's Disease Who Failed Biologic Therapies: A National Cohort Study
Claire Liefferinckx, Bram Verstockt, Ann Gils, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
November 29, 2021
Steroid-Free Deep Remission at One Year Does Not Prevent Crohn's Disease Progression: Long-Term Data From the TAILORIX Trial
David Laharie, Geert D'Haens, Maria Nachury, et al.
Journal of Pediatric Gastroenterology and Nutrition
|
February 3, 2016
Paediatric Crohn Disease: Disease Activity and Growth in the BELCRO Cohort After 3 Years Follow-up
Elisabeth De Greef, Ilse Hoffman, Francoise Smets, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
July 13, 2023
Outcome of Biological Therapies and Small Molecules in Ulcerative Proctitis: A Belgian Multicenter Cohort Study
Pauline Lemmens, Edouard Louis, Wouter Van Moerkercke, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
February 28, 2026
Long-term Safety of Upadacitinib in Patients with Inflammatory Bowel Disease: Integrated Analysis of Phase 2/3 Studies
Remo Panaccione, Julián Panés, Laurent Peyrin-Biroulet, et al.
Lancet (London, England)
|
March 5, 2023
Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies
William J Sandborn, Séverine Vermeire, Laurent Peyrin-Biroulet, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
June 5, 2026
The Efficacy and Safety of Etrasimod in Mildly to Moderately Active Ulcerative Colitis: Results from the Phase 2 GLADIATOR Trial
Silvio Danese, Martina Goetsch, Laurent Peyrin-Biroulet, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
September 24, 2022
I-CARE, a European Prospective Cohort Study Assessing Safety and Effectiveness of Biologics in Inflammatory Bowel Disease
Laurent Peyrin-Biroulet, Jean-François Rahier, Julien Kirchgesner, et al.
Journal of Crohn'S & Colitis
|
June 15, 2024
Impact of Prior Biologic or Janus Kinase Inhibitor Therapy on Efficacy and Safety of Etrasimod in the ELEVATE UC 52 and ELEVATE UC 12 Trials
Séverine Vermeire, Bruce E Sands, Laurent Peyrin-Biroulet, et al.
The Lancet. Gastroenterology & Hepatology
|
January 14, 2023
Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial
Edouard Louis, Matthieu Resche-Rigon, David Laharie, et al.
Page
of 10
Search research articles
Search
Showing results (81-90 of 99) with videos related to
Sort By:
Page
of 10
Journal of Crohn'S & Colitis
|
April 17, 2019
Long-term Clinical Effectiveness of Ustekinumab in Patients with Crohn's Disease Who Failed Biologic Therapies: A National Cohort Study
Claire Liefferinckx, Bram Verstockt, Ann Gils, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
November 29, 2021
Steroid-Free Deep Remission at One Year Does Not Prevent Crohn's Disease Progression: Long-Term Data From the TAILORIX Trial
David Laharie, Geert D'Haens, Maria Nachury, et al.
Journal of Pediatric Gastroenterology and Nutrition
|
February 3, 2016
Paediatric Crohn Disease: Disease Activity and Growth in the BELCRO Cohort After 3 Years Follow-up
Elisabeth De Greef, Ilse Hoffman, Francoise Smets, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
July 13, 2023
Outcome of Biological Therapies and Small Molecules in Ulcerative Proctitis: A Belgian Multicenter Cohort Study
Pauline Lemmens, Edouard Louis, Wouter Van Moerkercke, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
February 28, 2026
Long-term Safety of Upadacitinib in Patients with Inflammatory Bowel Disease: Integrated Analysis of Phase 2/3 Studies
Remo Panaccione, Julián Panés, Laurent Peyrin-Biroulet, et al.
Lancet (London, England)
|
March 5, 2023
Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies
William J Sandborn, Séverine Vermeire, Laurent Peyrin-Biroulet, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
June 5, 2026
The Efficacy and Safety of Etrasimod in Mildly to Moderately Active Ulcerative Colitis: Results from the Phase 2 GLADIATOR Trial
Silvio Danese, Martina Goetsch, Laurent Peyrin-Biroulet, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
September 24, 2022
I-CARE, a European Prospective Cohort Study Assessing Safety and Effectiveness of Biologics in Inflammatory Bowel Disease
Laurent Peyrin-Biroulet, Jean-François Rahier, Julien Kirchgesner, et al.
Journal of Crohn'S & Colitis
|
June 15, 2024
Impact of Prior Biologic or Janus Kinase Inhibitor Therapy on Efficacy and Safety of Etrasimod in the ELEVATE UC 52 and ELEVATE UC 12 Trials
Séverine Vermeire, Bruce E Sands, Laurent Peyrin-Biroulet, et al.
The Lancet. Gastroenterology & Hepatology
|
January 14, 2023
Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial
Edouard Louis, Matthieu Resche-Rigon, David Laharie, et al.
Page
of 10